Clinical Trials /

A Study of LY3435151 in Participants With Solid Tumors

NCT04099277

Description:

The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.

Related Conditions:
  • Malignant Solid Tumor
Recruiting Status:

Terminated

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: A Study of LY3435151 in Participants With Solid Tumors
  • Official Title: A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors

Clinical Trial IDs

  • ORG STUDY ID: 17364
  • SECONDARY ID: J1Q-MC-JZIA
  • NCT ID: NCT04099277

Conditions

  • Solid Tumor
  • Triple-negative Breast Cancer
  • Gastric Adenocarcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Cervical Carcinoma
  • High Grade Serous Ovarian Carcinoma
  • Hepatocellular Carcinoma
  • Undifferentiated Pleomorphic Sarcoma
  • Leiomyosarcoma

Interventions

DrugSynonymsArms
LY3435151Part A: 10 milligrams (mg) LY3435151
PembrolizumabPart B: LY3435151 + Pembrolizumab Dose Escalation

Purpose

The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.

Trial Arms

NameTypeDescriptionInterventions
Part A: 10 milligrams (mg) LY3435151ExperimentalParticipants received intravenous (IV) push or IV bolus infusion of 10 mg LY3435151.
  • LY3435151
Part B: LY3435151 + Pembrolizumab Dose EscalationExperimentalPembrolizumab was not administered as study was terminated before completion of Part A of the dose escalation period.
  • LY3435151
  • Pembrolizumab
Part C: LY3435151 Dose ExpansionExperimentalParticipants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
  • LY3435151
Part D: LY3435151 + Pembrolizumab Dose ExpansionExperimentalParticipants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
  • LY3435151
  • Pembrolizumab

Eligibility Criteria

        Inclusion Criteria:

          -  Participant must have certain types of cancer, which your study doctor will discuss
             with you

          -  Participant must have stopped other forms of treatment for cancer, which your study
             doctor will discuss with you

          -  Participant must be able and willing to provide a sample of your tumor before
             beginning treatment and once while on treatment. For certain tumor types, the outcome
             of the biopsy may exclude you from the study treatment (for Phase 1b)

          -  Participant must agree to use birth control

          -  Participant must have progressed through or are intolerant to therapies with known
             clinical benefit, which your study doctor will discuss with you

        Exclusion Criteria:

          -  Participant must not have a history of tuberculosis, uncontrolled HIV or uncontrolled
             hepatitis B or C virus infection

          -  Participant must not have an autoimmune disease, which your study doctor will discuss
             with you

          -  Participant must not use corticosteroids, which your study doctor will discuss with
             you

          -  Participant must not have heart disease, Crohn's disease or brain cancer

          -  Participant must not be pregnant or breastfeeding
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Number of Participants With LY3435151 Dose-Limiting Toxicities (DLTs)
Time Frame:Baseline through Cycle 2 (21 Day Cycles)
Safety Issue:
Description:A DLT is defined as an Adverse Event that is likely related to the study medication or combination, and fulfills any one of the following criteria, graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0: Any death not clearly due to the underlying disease or extraneous causes Neutropenic fever 2. Any Grade ≥3 non-hematologic toxicity Grade ≥4 neutropenia or thrombocytopenia >7 days Grade ≥3 thrombocytopenia with bleeding Grade ≥3 nausea/vomiting or diarrhea>72 hours with adequate antiemetic and other supportive care Grade ≥3 fatigue ≥1 week Grade ≥3 electrolyte abnormality that lasts>72 hours, unless the Participant has clinical symptoms, in which case all Grade 3+electrolyte abnormality regardless of duration should count as a DLT Grade ≥3 prolongation of QT interval corrected using the Fridericia formula on 2 separate electrocardiogram readings approximately 5 min apart.

Secondary Outcome Measures

Measure:Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3435151
Time Frame:Cycle 1 Day 1 (C1D1) (Predose, 1, 3 hour (hr), C1D2 (24 hr), C1D4 (72hr), C1D8 (168hr), C1D15 (336hr)
Safety Issue:
Description:Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3435151.
Measure:PK: Cmax of LY3435151 in Combination With Pembrolizumab
Time Frame:Predose Cycle 1 Day 1 through Predose Cycle 5 Day 1 (21 Day Cycles)
Safety Issue:
Description:PK: Cmax of LY3435151 in Combination with Pembrolizumab.
Measure:Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR)
Time Frame:Baseline through Disease Progression or Death (Up to 4 Months)
Safety Issue:
Description:Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants per cohort with at least 1 measurable lesion, multiplied by 100.
Measure:Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and Stable Disease
Time Frame:Baseline through Measured Progressive Disease (Up to 4 Months)
Safety Issue:
Description:Disease Control Rate (DCR) is the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Measure:Duration of Response (DoR)
Time Frame:Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up to 4 Months)
Safety Issue:
Description:DOR is the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Measure:Time to Response (TTR)
Time Frame:Baseline to Date of CR or PR (Up to 4 Months)
Safety Issue:
Description:Time to response (TTR) is defined as the time from the date of start of treatment to the date measurement criteria for confirmed CR or PR (whichever is first recorded) are first met. For participants who are not known to have achieved CR or PR as of the data inclusion cut-off date, TTR will be censored at the date of the last objective disease assessment prior the date of any subsequent systematic anticancer therapy.
Measure:Progression Free Survival (PFS)
Time Frame:Baseline to Objective Progression or Death Due to Any Cause (Up to 4 Months)
Safety Issue:
Description:PFS time was measured from the date of randomization until the first radiographic documentation of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Terminated
Lead Sponsor:Eli Lilly and Company

Trial Keywords

  • immunotherapy
  • CD226 agonist

Last Updated

August 31, 2021